Kindstar Globalgene Technology, Inc. (HK:9960) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kindstar Globalgene Technology, Inc. has voluntarily announced its acquisition of approximately 11.38% equity interest in Beijing Bofurui Gene Diagnostic Technology Co., Ltd., a leader in transplantation esoteric testing and professional services in China. The acquisition, valued at RMB31,876,000, is part of Kindstar’s strategy to enhance its esoteric testing capabilities and market influence in transplantation services. The deal does not make the target company a subsidiary, nor will it be reflected in Kindstar’s consolidated financial statements.
For further insights into HK:9960 stock, check out TipRanks’ Stock Analysis page.